Rabies - A Pipeline Analysis Report 2018| Technavio | Financial Buzz

Rabies – A Pipeline Analysis Report 2018| Technavio

Technavio has announced its latest pipeline analysis report on the rabies
market. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat chondrosarcoma.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for rabies, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the coming years.

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

Rabies: Market overview

Rabies is a viral disease that causes acute irritation of the brain in
humans and other animals. Rabies is spread to humans from animals such
as dogs, cats, and cows. Rabies can be spread when an infected animal
scratches or bites humans. The saliva from an infected animal can also
spread rabies if it comes in contact with a human body part. Some of the
symptoms of rabies include incubation, prodrome, acute neurologic pain,
and coma.

According to a senior analyst at Technavio for infectious and rare
diseases, “According to a major research, the cases of human rabies
in the US is very rare. There are only one to three cases reported
annually for human rabies. There were only 8 cases of human rabies that
were reported in the US in the last 10 years. Dog rabies vaccination
programs have stopped the natural spread of rabies among domestic dogs.”

Rabies: Segmentation analysis

This market research report segments the rabies market based on
therapies employed (monotherapy, combination and unknown), RoA
(intradermal, intradermal/intramuscular, intramuscular, and unknown),
therapeutic modality (monoclonal antibody, small molecule, vaccine, and
unknown), targets (innate immune cells, immune system, immunoglobin,
rabies glycoprotein, and unknown), MoA (innate immune cell activator,
immunostimulant, immunoglobulin replacement, rabies glycoprotein
encoder, unknown, and immunoglobulin activator), and recruitment status
(completed, active not recruiting, and unknown).

Monotherapy includes the use of a single drug to treat a disorder or a
disease. In the current pipeline, around 42.86% of the molecules that
are being investigated for the treatment of rabies are monotherapy.

In case of intradermal RoA, the drugs are applied within the layers of
the skin. About 4.77% of the total therapeutics are being developed for
intradermal RoA.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005663/en/